Chair:
    Peter Mulders, MD, PhD 
    University Medical Center Nijmegen
    Nijmegen, The Netherlands


Moderator:
    Lee Lokey, MD
    Senior Medical Director
    prIME Oncology
    Atlanta, Georgia, United States


Faculty:
    Alastair W. S. Ritchie, MD
    Medical Research Council
    London, United Kingdom

  
    Camillo Porta, MD
    IRCCS San Matteo University Hospital
    Pavia, Italy

   
    Thomas Powles, MD
    St Bartholomews Hospital
    London, United Kingdom

   
    Kurt Miller, MD
    Benjamin Franklin Medical Center
    Berlin, Germany

Friday, 9 October 2009
19.30-22.00 Welcome reception and dinner
Saturday, 10 October 2009
08.30	Welcome, introduction & demographics questions Peter Mulders, MD, PhD Lee Lokey, MD
08.50	Case #1—Renal cell carcinoma: The emerging role of adjuvant and neoadjuvant therapy Alastair W. S. Ritchie, MD
09.20	Case #2—Intermediate-risk renal cell carcinoma: Best choice and sequencing of therapy Camillo Porta, MD
09.50	Interactive debate—Renal cell carcinoma: Is there a need for another VEGF tyrosine kinase inhibitor? Pro: Thomas Powles, MD Contra: Peter Mulders, MD, PhD
10.30	Break
11.00	Clinical Opinion Poll
11.20	Case #3—PSA-only relapse following local therapy for high-risk prostate cancer Kurt Miller, MD
11.55	Case #4—Transitional cell carcinoma of the bladder: What’s the best approach? Thomas Powles, MD
12.25	Case #5—Nonseminomatous germ cell tumor of the testis: A multidisciplinary approach Discussant: Kurt Miller, MD Commentary: Camillo Porta, MD
13.00	Lunch
14.00	Case #6—Hormone-responsive prostate cancer with bone metastases: How should therapy be sequenced? Peter Mulders, MD, PhD
14.40	Case #7—Castration-resistant prostate cancer: Optimal management of a patient with good performance status Camillo Porta, MD
15.10	Ask the Experts
15.30	Concluding remarks